Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Biologics or biological products are medicines made from living organisms through highly complex manufacturing processes, and must be handled and administered under carefully monitored conditions. Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, blood products, cytokines, growth factors, fusion proteins, insulin, interferon, and vaccines. Biologics are used to prevent, treat or cure various diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis, and autoimmune disorders.

The market in the Middle East is expected to witness significant growth, owing to increasing healthcare expenditure. For instance, in 2018, the UAE healthcare expenditure was US$ 13.7 billion, which is expected to reach US$ 18.3 Bn by 2023.

The MENA biologics & biosimilars market is estimated to be valued at US$ 442.5 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027).

Figure 1: MENA Biologics & Biosimilars Market Share (%) Analysis, By Therapeutic Application, 2020

MENA Biologics & Biosimilars  | Coherent Market Insights

MENA Biologics & Biosimilars Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to declining outpatients’ visits, manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases such as cardiovascular, diabetic and cancer.

Moreover, the coronavirus pandemic has negatively impacted development, production, and supply of drugs and affected businesses of various companies operating in the healthcare sector across the globe. The pandemic has led to closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of products.

Thus, COVID-19 pandemic has affected the economy in three main ways: 1) by directly affecting the production and demand,  2) by creating disruptions in distribution channels, and 3) through its financial impact on companies and financial markets.

Supply chain and manufacturing activities in India, China, the U.S., and other countries have been disrupted due to lockdowns, while countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation of drugs and medical devices.

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the MENA biologics & biosimilars market during the forecast period.

request-sample

MENA Biologics & Biosimilars Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 442.5 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.9% 2027 Value Projection: US$ 623.7 Mn
Geographies covered:
  • Gulf: Saudi Arabia, UAE, and Kuwait
  • Egypt
Segments covered:
  • By Product Type: Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin ( Epoetin Alfa, Binocrit ( 2000IU, 4000IU ), Eprex ( 2000IU, 4000IU), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit, Recormon)), Aflibercept (EYLEA), Ziv-Aflibercept (ZALTRAP))
  • By Therapeutic Application: Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, Others.
Companies covered:

F. Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited

Growth Drivers:
  • Increasing incidence of hemophilia
  • Increasing approvals and launches of novel products and strategic collaborations among key players
Restraints & Challenges:
  • High cost of treatment for hemophilia

Rising strategic collaborations with leading pharmaceutical companies and research institutes for the development of novel biosimilar is driving growth of the MENA biologics & biosimilars market

Key players are involved in strategic collaborations with leading pharmaceutical companies and research institutes for the development of novel biosimilar. Such strategic collaborations are expected to create conducive environment for growth of the MENA biologics and biosimilar market in the near future.

For instance, in July 2018, Xbrane Biopharma AB (Xbrane) and STADA Arzneimittel AG (STADA) entered into a collaborative agreement for the development of Lucentis (ranibizumab) biosimilar to treat eye diseases, mainly neovascular age-related macular degeneration, diabetic-related macular edema, and retinal vein occlusion, covering Europe, the U.S., and some MENA and APAC markets.

In November 2017, Octapharma AG, in collaboration with Project SHARE, donated 30.5 million units of human cell-line derived recombinant factor VIII product, Nuwiq, for the treatment of patients with hemophilia A in emerging economies such as Bangladesh, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Myanmar, Nepal, and others.

MENA Biologics & Biosimilars Market- Restraints

High cost of treatment for hemophilia is a major factor, which is expected to hinder the market growth during the forecast period. Hemophilia is associated with high aggregate costs and imposes a high financial burden on individuals and healthcare systems in emerging economies. Hemophilia is a chronic condition that requires lifelong treatment, with individual costs varying based on disease severity, complications, and treatment regimen.

For instance, according to a cohort study conducted by National Center for Biotechnology Information (NCBI) in 2015, hemophilia treatment is expensive, particularly for patients with severe hemophilia. According to the study, severe hemophilia is associated with greater annual costs in both types of hemophilia. For instance, according to the study in NCBI in 2015, the annual cost required for the treatment of hemophilia A is around US$ 84,766.9 and hemophilia B is around US$ 122,877. Patients with factor VIII inhibitors have costs 3.3 times higher than patients without factor VIII inhibitors. Thus, high cost of therapy is expected to hinder the market growth during the forecast period.

Figure 2: MENA Biologics & Biosimilars Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

MENA Biologics & Biosimilars  | Coherent Market Insights

MENA Biologics & Biosimilars Market- Competitive Landscape

Key players operating in the MENA biologics & biosimilars market include F. Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. New technologies for manufacturing of biologics, which hold potential for the MENA biologics & biosimilars market growth.

Biologics are widely used to prevent, treat, diagnose or cure a variety of diseases such as cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.

Furthermore, Rapid reforms in the healthcare sector MENA region by government and multinational companies is expected to propel growth of the MENA biologics & biosimilars market. For Instance, In March 2020, The Ministry of Health (MOH) of Saudi Arabia signed a memorandum of understanding with Sanofi Saudi Arabia, to start localizing and transferring insulin industry technology locally in the Kingdom of Saudi Arabia and the possibility of external export to the GCC countries and the Middle East region

Market Dynamics

The MENA biologics & biosimilars market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of hemophilia. According to the World Federation Hemophilia Global Survey, there was approximately 5,050 people with hemophilia (PWH) in Egypt in 2013.

According to the Annual Global Survey, around 418 people were suffering from hemophilia in Saudi Arabia in 2016.

Moreover, increasing number of novel technology launches is expected to drive growth of the market.

For instance, In July 2018, Xbrane Biopharma AB (Xbrane) and STADA Arzneimittel AG (STADA) entered into a collaborative agreement for the development of Lucentis (ranibizumab) biosimilar for the treatment of several eye diseases mainly neovascular age-related macular degeneration, diabetic-related macular edema, and retinal vein occlusion, covering Europe, the U..S and some MENA and APAC markets.

 Key features of the study:

  • This report provides in-depth analysis of the MENA biologics & biosimilars market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) during the forecast period 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the MENA biologics & biosimilars market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Hoffmann-la Roche Ag, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Amgen, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological up gradation, market expansion, and marketing tactics
  • The MENA biologics & biosimilars market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the MENA biologics & biosimilars market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • MENA Biologics & Biosimilars Market, By Product Type:
    • Influenza Vaccines
    • Factor VIII
      • Xyntha
      • Octanate
      • Kovaltry
      • Advate
      • Koate
      • Adynovate
      • Kogenate
      • Hemlibra
      • Elocta
      • Recombinate
      • Feiba
      • Immunate
      • Alphanate
      • Novoeight
    • Erythropoietin
      • Epoetin Alfa
        • Binocrit
          • 2000IU
          • 4000IU
        • Eprex
          • 2000IU
          • 4000IU
        • Darbepoietin Alfa (Aranesp)
        • Epoetin Alfa-epbx (Retacrit, Recormon)
      • Aflibercept (EYLEA)
      • Ziv-Aflibercept (ZALTRAP)
  • MENA Biologics & Biosimilars Market, By Therapeutic Application:
    • Hemophilia
    • Age-related Macular Degeneration
    • Kidney Diseases
    • Influenza
    • Others
  • MENA Biologics & Biosimilars Market, By Region/ Country:
    • Gulf
      • By Country:
        • Saudi Arabia
        • UAE
        • Kuwait
      • By Product Type:
        • Influenza Vaccines
        • Factor VIII
          • Xyntha
          • Octanate
          • Kovaltry
          • Advate
          • Koate
          • Adynovate
          • Kogenate
          • Hemlibra
          • Elocta
          • Recombinate
          • Feiba
          • Immunate
          • Alphanate
          • Novoeight
        • Erythropoietin
          • Epoetin Alfa
            • Binocrit
              • 2000IU
              • 4000IU
            • Eprex
              • 2000IU
              • 4000IU
            • Darbepoietin Alfa (Aranesp)
            • Epoetin Alfa-epbx (Retacrit, Recormon)
          • Aflibercept (EYLEA)
          • Ziv-Aflibercept (ZALTRAP)
      • By Therapeutic Application:
        • Hemophilia
        • Age-related Macular Degeneration
        • Kidney Diseases
        • Influenza
        • Others
    • Egypt
      • By Product Type:
        • Influenza Vaccines
        • Factor VIII
          • Xyntha
          • Octanate
          • Kovaltry
          • Advate
          • Koate
          • Adynovate
          • Kogenate
          • Hemlibra
          • Elocta
          • Recombinate
          • Feiba
          • Immunate
          • Alphanate
          • Novoeight
        • Erythropoietin
          • Epoetin Alfa
            • Binocrit
              • 2000IU
              • 4000IU
            • Eprex
              • 2000IU
              • 4000IU
            • Darbepoietin Alfa (Aranesp)
            • Epoetin Alfa-epbx (Retacrit, Recormon)
          • Aflibercept (EYLEA)
          • Ziv-Aflibercept (ZALTRAP)
      • By Therapeutic Application:
        • Hemophilia
        • Age-related Macular Degeneration
        • Kidney Diseases
        • Influenza
        • Others
  • Company Profiles
    • Hoffmann-la Roche Ag
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Regeneron Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Amgen, Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Therapeutic Application
      • Market Snippet, By Region/Country
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Biologics & Biosimilars Overview
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Epidemiology
    • Registered Products
    • Patent Expiry Analysis
    • Recombinant (Factor VIII) & Patient Population (Saudi Arabia)
  4. MENA Biologics & Biosimilars Market - Impact of Coronavirus (Covid-19) Pandemic
    • Overall Impact
    • New Developments
    • Strategies
  5. MENA Biologics & Biosimilars Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Influenza Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Factor VIII
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Xyntha
        • Octanate
        • Kovaltry
        • Advate
        • Koate
        • Adynovate
        • Kogenate
        • Hemlibra
        • Elocta
        • Recombinate
        • Feiba
        • Immunate
        • Alphanate
        • Novoeight
    • Erythropoietin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Epoetin Alfa
          • Binocrit
            • 2000IU
            • 4000IU
          • Eprex
            • 2000IU
            • 4000IU
        • Darbepoietin Alfa (Aranesp)
        • Epoetin Alfa-epbx (Retacrit, Recormon)
          •  
    • Aflibercept (EYLEA)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Ziv-Aflibercept (ZALTRAP)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. MENA Biologics & Biosimilars Market, By Therapeutic Application, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hemophilia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Age-related Macular Degeneration
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Kidney Diseases
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Influenza
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. MENA Biologics & Biosimilars Market, By Region/Country, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region/Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region/Country, 2017 – 2027
      • Regional/ Country Trends
    • Gulf
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Saudi Arabia
        • UAE
        • Kuwait
    • Egypt
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Million)
  8. Competitive Landscape
    • Company Profiles
      • F. Hoffmann-la Roche Ag
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 15 market data tables and 41 figures on "MENA Biologics & Biosimilars Market” - Forecast to 2027”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.